Maze Therapeutics

MAZENasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.586 B

$28.65 +0.42%

Close of 7 Aug 2026

Revenue

$167.5M

#2359 by revenue

Earnings

-$131.1M

Loss-making

Shares outstanding

55,345,261

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#37Recursion PharmaceuticalsRXRX$1.72B
#38ImmunocoreIMCR$1.64B
#39Maze TherapeuticsMAZE$1.59B
#40SL ScienceSLBT$1.50B
#41Vir BiotechnologyVIR$1.49B

Where these numbers come from

Share counts and financials for Maze Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.